Immunome, Inc. (IMNM)
NASDAQ: IMNM · Real-Time Price · USD
21.86
-0.03 (-0.14%)
At close: Feb 27, 2026, 4:00 PM EST
21.85
-0.01 (-0.05%)
After-hours: Feb 27, 2026, 7:35 PM EST
Immunome Employees
Immunome had 118 employees as of December 31, 2024. The number of employees increased by 63 or 114.55% compared to the previous year.
Employees
118
Change (1Y)
63
Growth (1Y)
114.55%
Revenue / Employee
$57,613
Profits / Employee
-$1,325,851
Market Cap
2.41B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 118 | 63 | 114.55% |
| Dec 31, 2023 | 55 | 18 | 48.65% |
| Dec 31, 2022 | 37 | -2 | -5.13% |
| Dec 31, 2021 | 39 | 16 | 69.57% |
| Dec 31, 2020 | 23 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Zai Lab | 1,869 |
| Ultragenyx Pharmaceutical | 1,294 |
| Telix Pharmaceuticals | 1,184 |
| Arcus Biosciences | 627 |
| Adaptive Biotechnologies | 619 |
| Ascentage Pharma Group International | 605 |
| Disc Medicine | 142 |
| Mesoblast | 81 |
IMNM News
- 5 days ago - Immunome to Present at Upcoming Investor Conferences - Business Wire
- 23 days ago - Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 24 days ago - Immunome to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 - Business Wire
- 7 weeks ago - Immunome to Present at 44th Annual J.P. Morgan Healthcare Conference - Business Wire
- 2 months ago - Immunome: Maintaining "Strong Buy" On Successful RINGSIDE Trial With Varegacestat - Seeking Alpha
- 2 months ago - Immunome Announces Pricing of Public Offering of Common Stock - Business Wire
- 2 months ago - Immunome Announces Proposed Public Offering of Common Stock - Business Wire
- 2 months ago - Immunome's experimental drug meets main goal in late-stage study - Reuters